Quantcast

Latest AcelRx Pharmaceuticals Inc. Stories

2014-10-16 08:30:45

Patent estate includes thirteen issued U.S. patents, thirty patents worldwide REDWOOD CITY, Calif., Oct. 16, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update regarding its growing patent estate which totals 30 issued patents worldwide. These issued patents cover AcelRx's sufentanil...

2014-10-10 08:23:54

Data from Sublingual Sufentanil Development Program Highlights Onset of Analgesia, Safety and Effect of Gender on Analgesic Response REDWOOD CITY, Calif., Oct. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) today announced that multiple moderated poster presentations will be made at the upcoming American Society of Anesthesiologists (ASA 2014) meeting October 11(th) to October 15(th), 2014 at the Ernest N. Morial Convention Center in New Orleans, LA. The annual...

2014-10-06 08:27:55

REDWOOD CITY, Calif., Oct. 6, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that a new data analysis from previously reported phase 3 studies evaluating the sufentanil sublingual tablet system (SSTS) for the treatment of moderate-to-severe acute pain will be presented at the International...

2014-09-26 08:25:17

REDWOOD CITY, Calif., Sept. 26, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update on the plans for the resubmission of the Company's New Drug Application (NDA) for Zalviso(TM) (sufentanil sublingual tablet system). The Company recently held a teleconference with representatives from the...

2014-09-10 08:29:52

REDWOOD CITY, Calif., Sept. 10, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of a pharmacoeconomic analysis of the cost of intravenous patient-controlled analgesia with opioids based on current literature and data from over 500 U.S. hospitals. The manuscript entitled 'Cost...

2014-09-04 08:26:07

REDWOOD CITY, Calif., Sept. 4, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the publication of the results of a study to evaluate patient satisfaction with a novel sublingual sufentanil patient-controlled analgesia (PCA) system compared to the standard intravenous PCA for the management of...

2014-08-27 08:27:21

REDWOOD CITY, Calif., Aug. 27, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at the FBR Healthcare One on One Conference and presenting at the Morgan Stanley Global Healthcare Conference. Details of the two events are as follows: FBR Healthcare One...

2014-08-11 16:27:34

REDWOOD CITY, Calif., Aug. 11, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2014. On July 25, 2014, AcelRx announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Company's new...

2014-08-08 08:25:39

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that senior management will be participating at three upcoming investor events. Details of the three events are as follows: Canaccord 34(th) Annual Growth ConferenceDate: Wednesday August 13(th) Location: Boston,...

2014-07-26 00:20:52

REDWOOD CITY, Calif., July 25, 2014 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso(TM) (sufentanil sublingual tablet system). The Company is currently...


Word of the Day
bellycheer
  • Good cheer; viands.
  • To revel; to feast.
The word 'bellycheer' may come from 'belle cheer', "good cheer".
Related